Congressional Commission Warns US Pharma Depends on China Biotech
The National Security Commission on Emerging Biotechnology, a congressional body, warned in a Nov. 18 brief that China is working to control the pharmaceutical supply chain from manufacturing to drug discovery, and that U.S. drugmakers' growing licensing deals with Chinese biotechs are deepening American dependence. The commission said China published a pharmaceutical-focused follow-on to its 15th Five-Year Plan in September setting 2030 goals for more first-in-class drugs and global sales, and analyzed 57 deals between the 15 largest U.S. drugmakers and 42 Chinese biotechs from January 2023 to October 2026, finding rising up-front payments and escalating deal structures. It pointed to China's October proposal, not yet final, to restrict exports of certain next-generation biopharmaceutical technologies. The brief noted the FDA this month rejected a Chinese-invented lung cancer drug, and that generic drugs rely primarily on India and China for active ingredients while the U.S. accounts for only 12% of production.